Bariatric surgery versus injectable dual incretin agonist on weight loss, metabolic and novel coronary CT imaging biomarkers
Obesity is a chronic disease and rising global health problem associated with significant morbidity and mortality, often due to cardiovascular disease (CVD). Bariatric surgery is performed for obesity and may reduce CVD risk, however, access is limited by long waitlist. Recently, a glucose dependent insulinotropic polypeptide and glucagon-like peptide-1 dual receptor agonist (GIP/GLP-1 RA) medication was shown to reduce weight by ~20% (i.e., more than GLP-1 RA alone) and improve CVD risk factors in obesity. This once-weekly injectable medication offers a non-invasive alternative to surgical intervention, but no studies have compared GIP/GLP-1 RA with bariatric surgery. Importantly, the effects of these treatments on novel coronary biomarkers, which are predictors of adverse outcomes, remain unclear.Suitable for MPhil or PhD candidate.SCHOLARSHIP VALUE: $105,000 AUD
Please see conditions
Basis of award
Domestic students only.Must be employed by South Metro Health Service as a Pre-clinical Medical staff member.
Australian Citizen, Australian Permanent Resident
University of Western Australia